This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
If you ask why you keep overspending, you're not alone. This section breaks down frequent triggers and offers concrete fixes to align spending with goals.
22,481 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
The Antinozzi Group rejoined Compass in Houston after a period with REMAX, led by Joe Antinozzi and Kristin Weaver. I...
On July 1, 2026, SOXL tumbled 16% in a single session as its leveraged structure amplified the move. The fallout reve...
A new partnership between Palantir and NVIDIA gives government and critical infrastructure clients on-prem AI capabil...
The Magnificent 7 erased $2.3 trillion in market value in June, signaling investors are reassessing AI bets and the t...
A growing strategy lets corporate executives push $100K+ into a single-year 401K by leveraging the 415(C) rule and af...
Meta unveils a $6.5 billion plan to manufacture next-gen MTIA AI chips with Samsung Foundry, aiming to strengthen its...
Hon Hai Precision posts a 40% quarterly jump, powered by AI server demand. The result highlights ongoing AI spending ...
Chipotle and Microsoft have taken divergent paths in 2026. CMG rides restaurant-demand strength while MSFT grapples w...
A federal judge revived a fraud claim in the Genesis Yield class action against Barry Silbert and Digital Currency Gr...
SK Hynix is lining up a U.S. listing on Nasdaq, aiming to raise about $28 billion as memory chips ride AI demand and ...
Oil futures climbed after the U.S. Treasury canceled a license that allowed limited Iranian oil sales, triggering a f...